1. Home
  2. ABCL vs PHAT Comparison

ABCL vs PHAT Comparison

Compare ABCL & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$4.12

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$15.49

Market Cap

942.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABCL
PHAT
Founded
2012
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
942.6M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
ABCL
PHAT
Price
$4.12
$15.49
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
$7.75
$17.33
AVG Volume (30 Days)
3.5M
911.3K
Earning Date
02-26-2026
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,325,000.00
$147,190,000.00
Revenue This Year
$25.45
$220.37
Revenue Next Year
$10.07
$83.14
P/E Ratio
N/A
N/A
Revenue Growth
7.17
460.30
52 Week Low
$1.89
$2.21
52 Week High
$6.52
$18.31

Technical Indicators

Market Signals
Indicator
ABCL
PHAT
Relative Strength Index (RSI) 62.59 47.30
Support Level $3.34 $15.43
Resistance Level $4.20 $18.09
Average True Range (ATR) 0.21 0.91
MACD 0.09 -0.13
Stochastic Oscillator 88.37 12.66

Price Performance

Historical Comparison
ABCL
PHAT

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: